Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review
Background: Post-infectious irritable bowel syndrome (PI-IBS) prevalence, small intestinal bacterial overgrowth (SIBO), altered microbiota, low-grade inflammation, and antibiotic therapy in IBS are all controversial issues. Aims: To conduct an evidence-based review of these factors. Methods: A revie...
Main Authors: | Max Schmulson, María Victoria Bielsa, Ramón Carmona-Sánchez, Angélica Hernández, Aurelio López-Colombo, Yolanda López Vidal, Mario Peláez-Luna, José María Remes-Troche, José Luis Tamayo, Miguel Angel Valdovinos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-04-01
|
Series: | Revista de Gastroenterología de México (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2255534X14000218 |
Similar Items
-
Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01) -
The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials
by: T. Rokkas, et al.
Published: (2020-07-01) -
<i>Bacillus</i> spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome
by: Adrian Catinean, et al.
Published: (2019-08-01) -
Guidelines on the management of irritable bowel syndrome
by: Anna Pietrzak, et al.
Published: (2018-09-01) -
Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
by: Xiaojun Zhuang, et al.
Published: (2020-06-01)